<DOC>
	<DOCNO>NCT00294996</DOCNO>
	<brief_summary>The purpose study examine safety effectiveness drug combination Myocet , paclitaxel trastuzumab compare paclitaxel trastuzumab without Myocet , first line treatment patient metastatic HER2+ breast cancer .</brief_summary>
	<brief_title>Trial Myocet Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Metastatic Her2+ Breast cancer FISH analysis No prior chemotherapy metastatic disease Measurable disease normal leave ventricular ejection fraction prior doxorubicin treatment exceed 300 mg/m2 epirubicin exceed 600 mg/m2 relapse within 12 month completion adjuvant trastuzumab , taxane anthracycline therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Metastatic Her2+ Breast cancer</keyword>
	<keyword>Myocet</keyword>
	<keyword>liposomal doxorubicin</keyword>
	<keyword>trastuzumab</keyword>
</DOC>